International Prognostic Index May Identify Risk Groups for CLL

Share this content:
An international prognostic index for chronic lymphocytic leukemia that combines genetic, biochemical, and clinical parameters into a prognostic model.
An international prognostic index for chronic lymphocytic leukemia that combines genetic, biochemical, and clinical parameters into a prognostic model.

An international prognostic index for chronic lymphocytic leukemia (CLL-IPI) that combines genetic, biochemical, and clinical parameters into a prognostic model may be able to discriminate among patients into four subgroups, according to a study published in The Lancet Oncology.

Researchers from The International CLL-IPI working group consortium looked at 3,472 treatment-naïve patients with CLL through a systematic search of the Cochrane Hematological Malignancies Group of MEDLINE, Embase, and Central databases of prospective, clinical phase 2 and 3 trials that were published between January 1950 and December 2010.

They performed a univariate analysis and multivariate analyses using 27 baseline factors, with overall survival as an endpoint. They assessed the discriminatory value using C-statistics and also the validity and reproducibility of the CLL-IPI through subgroup analysis.

Furthermore, they used two additional datasets from the Mayo Clinic (MAYO cohort) as well as the SCALE Scandinavian population-based case-control study (SCAN cohort) as external-validation datasets.

Among the observed patients, 2,308 were randomly segregated into a training dataset and 1,164 into the internal-validation dataset. Within the training dataset, 5 prognostic factors were identified: TP53 status, IGHV mutational status, serum β2-microglobulin concentration, clinical stage, and age.

Through a weighted grading of the independent factors, the researchers created a prognostic index that identified 4 risk groups (low, intermediate, high, and very high risk) within the training dataset with a significantly different overall survival at 5 years. They confirmed these risk groups in the internal-validation and external-validation datasets.

RELATED: Study Confirms Activity of Venetoclax in Relapsed/Refractory Del(17p) CLL

“The CLL-IPI will allow a more targeted management of patients with CLL in clinical practice and in trials testing novel drugs,” the authors concluded.

Reference

  1. The International CLL-IPI working group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. [published online ahead of print May 13, 2016.] doi: http://dx.doi.org/10.1016/S1470-2045(16)30029-8.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs